



บริษัท ดีโอดี ไบโอเทค จำกัด(มหาชน)

เลขที่ 111 หมู่ที่ 2 ตำบลท่าจีน อำเภอเมืองสมุทรสาคร จังหวัดสมุทรสาคร 74000

111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000

No. DOD006/2564

January 26th, 2021

Subject: Use of proceeds from initial public offering of ordinary shares

To: President

The Stock Exchange of Thailand

DOD Biotech Public Company Limited (“the Company”) made an initial public offering (“IPO”) of ordinary shares during June 12–14, 2018 in the amount of 110,000,000 shares each of Baht 0.50 par value at the offering price of Baht 9.30 per share, totaling Baht 1,023,000,000. After deduction of offering expenses, the proceeds from the IPO amount to Baht 987,240,850.

The company would link to report the use of capital increase from the IPO for July 1, 2020 to December 31, 2020 as follows:

Purposes of use (Unit: Baht million)	Amount earmarked	Resolution of the Board of Directors No. 8/2018 on 19/12/2018	Resolution of the 2019 Annual General Meeting on 30/04/20 19	Amount used during period (Jul 1, 2020 – Dec 31, 2020)	Accumulated amount used (Jun 15, 2018 – Dec 31, 2020)	Balance remaining (Dec 31, 2020)
1. Investment in raw material extraction plant and world-class research laboratory	100.00	100.00	260.00	-	73.23	186.77
2. Development of the Company’s new brand	200.00	200.00	-	-	-	-
3. Repayment of loans to financial institutions	50.00	50.00	46.89	-	46.89	-
4. Working capital for business operation	637.34	368.24	221.45	-	221.45	-



บริษัท ดีโอดี ไบโอเทค จำกัด(มหาชน)

เลขที่ 111 หมู่ที่ 2 ตำบลท่าจีน อำเภอเมืองสมุทรสาคร จังหวัดสมุทรสาคร 74000

111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000

Purposes of use (Unit: Baht million)	Amount earmarked	Resolution of the Board of Directors No. 8/2018 on 19/12/2018	Resolution of the 2019 Annual General Meeting on 30/04/20 19	Amount used during period (Jul 1, 2020 – Dec 31, 2020)	Accumulated amount used (Jun 15, 2018 – Dec 31, 2020)	Balance remaining (Dec 31, 2020)
5. Expansion of production capacity for dietary supplement products, introduction of new product packages, and warehouse building (related to existing business as disclosed in the Registration Statement for offer for sale of securities and draft prospectus)	-	120.90	120.90	-	120.90	-
6. Lending to a subsidiary for investment and expansion of contracted manufacturing of cosmetics – PCCA Laboratory Co., Ltd. (new business)	-	148.00	148.00	-	148.00	-
7. Use to repay loans from financial institution Which is intended for investment in PCCA (New Business)	-	-	150.00	-	150.00	-



บริษัท ดีโอดี ไบโอเทค จำกัด(มหาชน)

เลขที่ 111 หมู่ที่ 2 ตำบลท่าจีน อำเภอเมืองสมุทรสาคร จังหวัดสมุทรสาคร 74000

111 Moo 2 TambonThachin, Amphurmuangsamutsakhon, Samutsakhon 74000

Purposes of use (Unit: Baht million)	Amount earmarked	Resolution of the Board of Directors No. 8/2018 on 19/12/2018	Resolution of the 2019 Annual General Meeting on 30/04/20 19	Amount used during period (Jul 1, 2020 – Dec 31, 2020)	Accumulated amount used (Jun 15, 2018 – Dec 31, 2020)	Balance remaining (Dec 31, 2020)
8.Use investment in subsidiaries that operate direct sale business (New business)	-	-	40.00	-	40.00	-
Total	987.24	987.24	987.24	-	800.47	186.77

Please be informed accordingly.

Yours sincerely,

Miss Suwarin Konthong

Director